CASE REPORT article
Front. Oncol.
Sec. Cancer Immunity and Immunotherapy
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1654431
This article is part of the Research TopicNew Tumor Immune Checkpoints and Their Applications in Tumor ImmunotherapyView all 4 articles
Bowen's disease treated with PD-1 inhibitor and chemotherapy
Provisionally accepted
- 1Chendu Second People’s Hospital, Chengdu, China
- 2West China Hospital of Sichuan University, Chengdu, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
A 51-year-old man with perianal Bowen's diseases,treated with tislelizumab and capecitabine chemotherapy,the tumor was significantly reduced and Improved quality of life. Key words: Bowen's diseases;Immune checkpoint inhibitors;chemotherapy
Keywords: Bowen's Disease, PD-1 inhibitor, chemotherapy, 5-fluorouracil, Cutaneous squamous cell carcinoma
Received: 26 Jun 2025; Accepted: 08 Sep 2025.
Copyright: © 2025 xie, chen, zhang and Peng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Xiaodong Peng, Chendu Second People’s Hospital, Chengdu, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.